山桑子 Bilberry × 末梢循環不良

結論:證據不足

Bilberry 對末梢循環的整體證據屬「機轉合理 + 傳統用途支持 + 現代 RCT 薄弱」之典型 C 級樣態。

D 🔴 D 反證據 證據不足 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🧪 反證據已標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用
⚗️ 研究進行中:本主題證據仍在累積、尚無定論;部分介入屬試驗階段,未必已在台上市或可購得。

Bilberry 對末梢循環的整體證據屬「機轉合理 + 傳統用途支持 + 現代 RCT 薄弱」之典型 C 級樣態。

核心人體證據(Berdonces 1979、Codega 1985、Teglio 1987 三項義大利舊試驗,n=60,173mg 花青素/日 × 30天)未被 PubMed 索引、多為單盲或無對照、僅報告主觀症狀緩解;2021 anthocyanin Meta-analysis(PMID 34977111)顯示莓類整體對 FMD 無顯著改善(p=0.096),bilberry 次群組亦無顯著血脂改善;2025 SIAPAV 義大利血管專家 Delphi 共識(PMID 41470775)明確將 anthocyanosides 排除於支持的 venoactive 營養品之外,理由為「證據異質、低確定性、萃取規格不一」。

雖然 WHO Vol.4 monograph (2009) 與 EMA/HMPC 2015 traditional-use 認可支持其用於 capillary leakage / peripheral vascular insufficiency / heaviness of legs,但 EMA 屬 traditional-use(≥30 年使用史,非 well-established efficacy),NCCIH 直接表明「Bilberry has not been clearly shown to be helpful for any health condition」,AHA/SVS 2024 PAD guideline 與 SVS 2025 update 對 bilberry 完全沉默。

Examine 無此 intervention(L1 absent)。

整體獨立判讀為 C — 機轉與傳統用途支持,現代高品質人體 RCT 不足。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.57
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 證據不足
信心度
76%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.50
L11 AI 複核獨立判讀
0.50
L2 PubMed原始文獻
0.60
L3 機轉生理合理性
0.65
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.568
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 0 positive),下層 RCT 不能推翻
  4. apply_hec_override — HEC-1 高階證據 negative — 強制由 B 改為 D
  5. tier_strict_requirement_check — Tier 條件達標,未降階
  6. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  7. decide_status — 依 tier + dispute 結果決定 status

Delphi Consensus on the Role of Venoactive Nutraceuticals in the Management of Chronic Venous Disease: SIAPAV Position Statement
PMID: 41470775 2025 Other n = 21
結論:In a 3-round modified Delphi of 21 Italian vascular specialists, MPFF, diosmin and hesperidin reached consensus as venoactive agents for CVD, while anthocyanosides (bilberry class) FAILED to reach the >=70% agreement threshold; panel cited 'heterogeneous and often low-certainty evidence' and 'variability in extract standardization' as key limitations.
學術資助
前往 PubMed
Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 RCTs and 15 Prospective Cohort Studies
PMID: 34977111 2021 統合分析 n = 263
結論:Pooled anthocyanin-rich berry intake produced no significant improvement in FMD (WMD 1.20%, 95% CI -0.21 to 2.60, p=0.096, I2=98.7%, 6 comparisons, 263 subjects); bilberry-only LDL-C subgroup (2 RCTs, n=81) showed WMD -4.90 mg/dL (p=0.112, NS) and triglycerides (3 RCTs, n=143) WMD +6.62 mg/dL (p=0.181, NS) — no significant peripheral vascular benefit isolated to bilberry.
🟢 高品質 學術資助 效應量:[object Object]
前往 PubMed
Effects of Vaccinium myrtillus anthocyanosides on arterial vasomotion
PMID: 1796918 1991 Animal Study
結論:V. myrtillus anthocyanosides induced rhythmic vasomotion in cheek pouch arterioles and terminal arterioles with higher frequency in smaller vessels, and increased vasomotion frequency and amplitude across all vessel orders in skeletal muscle networks — supporting a microcirculation-promoting mechanism (no human p-values; mechanistic only).
🟠 品質有限
前往 PubMed
An Updated Systematic Review of Vaccinium myrtillus Leaves: Phytochemistry and Pharmacology
PMID: 36678645 2022 系統性回顧
結論:Review of 2012–2022 literature on V. myrtillus leaves focused on antimicrobial and polyphenol composition; the review did NOT identify any new RCT data specifically addressing peripheral circulation or chronic venous insufficiency — peripheral-vascular evidence remains anchored in older Italian work (Berdonces 1979, Codega 1985, Teglio 1987) that is not PubMed-indexed.
學術資助
前往 PubMed

L4a US FDA
謹慎
The studies [of Bilberry] reveal that blood vessels are strengthened, circulation improves, blood glucose levels may be lowered, prevention of cell damage are all benefits that Bilberry may provide. 來源↗
L4b EU EFSA
中性
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
目前公告之健康食品保健功效共有13項:護肝、抗疲勞、調節血脂、調節血糖、免疫調節、骨質保健、牙齒保健、延緩衰老、促進鐵吸收、胃腸功能改善、輔助調節血壓、不易形成體脂肪、輔助調整過敏體質。(衛福部食藥署「健康食品概說暨導覽」) 來源↗
L4e WHO
支持
Uses supported by clinical data: Oral use for the symptomatic treatment of dysmenorrhoea associated with premenstrual syndrome, circulatory disorders in patients with capillary leakage or peripheral vascular insufficiency and ophthalmic disorders. Uses described in pharmacopoeias and well established documents: Oral use for the treatment of acute diarrhoea and local irritation or inflammation o… 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群(PTT Lifeismoney/e-shopping、Dcard、Mobile01)對山桑子的討論幾乎全集中在「護眼/夜間視力/搭配葉黃素」,且多為御松田、大研、BHK's、DHC、Aboca 等品牌業配導向。針對「末梢循環不良」此一適應症,社群中查無實際使用討論;末梢循環相關的山桑子論述僅見於康健、朵茉麗蔻等商業健康媒體(屬 L10d 業配污染來源),非真實鄉民經驗。

💬社群實感

無共識(社群討論集中於護眼用途,針對末梢循環不良查無鄉民實測心得)

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

葉黃素+山桑子護眼複方

代表來源 ↗
L10b · TFDA 法定身份 官方認定
🍽️一般食品

食品不得宣稱醫療效能

來源 ↗

  • 監督式運動治療(規律步行訓練)
  • 戒菸與心血管危險因子控制
  • Cilostazol
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v14 engine_version: v1.0 claim_id: CLM-COND-peripheral-circulation-INT-bilberry-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-peripheral-circulation-INT-bilberry-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "山桑子能改善末梢循環不良",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 1,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🔴 D 反證據"
  }
}